These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27604307)

  • 1. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
    Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
    Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease.
    Steinman L
    Eur J Immunol; 2014 Nov; 44(11):3201-5. PubMed ID: 25319369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self.
    Miska J; Bas E; Devarajan P; Chen Z
    Eur J Immunol; 2012 Oct; 42(10):2584-96. PubMed ID: 22777737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
    Yamazaki T; Pitt JM; Vétizou M; Marabelle A; Flores C; Rekdal Ø; Kroemer G; Zitvogel L
    Cell Death Differ; 2016 Jun; 23(6):1004-15. PubMed ID: 27082453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.
    Yshii L; Pignolet B; Mauré E; Pierau M; Brunner-Weinzierl M; Hartley O; Bauer J; Liblau R
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
    Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
    [No Abstract]   [Full Text] [Related]  

  • 8. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
    Yshii L; Bost C; Liblau R
    Front Immunol; 2020; 11():991. PubMed ID: 32655545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.
    Blachère NE; Orange DE; Santomasso BD; Doerner J; Foo PK; Herre M; Fak J; Monette S; Gantman EC; Frank MO; Darnell RB
    Eur J Immunol; 2014 Nov; 44(11):3240-51. PubMed ID: 25103845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3.
    Kowalczyk A; D'Souza CA; Zhang L
    Eur J Immunol; 2014 Apr; 44(4):1143-55. PubMed ID: 24338929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
    Shin JH; Park HB; Oh YM; Lim DP; Lee JE; Seo HH; Lee SJ; Eom HS; Kim IH; Lee SH; Choi K
    Blood; 2012 Jun; 119(24):5678-87. PubMed ID: 22538857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
    Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Graff JN; Li Z; Wu JD
    Sci Adv; 2017 May; 3(5):e1602133. PubMed ID: 28560327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
    Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.
    Wang Z; Davies JD
    Int Immunopharmacol; 2007 Feb; 7(2):249-65. PubMed ID: 17178393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4).
    Zhao Y; Wei Z; Yang H; Li X; Wang Q; Wang L; Li S
    Biomed Pharmacother; 2017 Jun; 90():147-152. PubMed ID: 28351777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cytotoxic T-lymphocyte antigen 4 on CD4+ and CD8+ T cells is increased in acute lung injury.
    Zhou Y; Tang L; Lin M; Xu S; Bai J; Song H
    DNA Cell Biol; 2013 Dec; 32(12):722-6. PubMed ID: 24028204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
    Kwek SS; Cha E; Fong L
    Nat Rev Cancer; 2012 Mar; 12(4):289-97. PubMed ID: 22378189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.